committees

The Company’s Audit Committee was set up in June 2014. The Audit Committee shall faithfully carry out the following duties and submit any proposals to Board of Directors meeting for discussions.

Audit Committee Scope of duties

1. Review and discuss the adoption or amendment for the internal control system

2. The assessment of the effectiveness of the internal control system

3. Review and discuss the adoption or amendment, of handling procedures for financial or operational actions of material significance, such as acquisition or disposal of assets, derivatives trading, extension of monetary loans to others, or endorsements or guarantees for others

4. Any matter that has a bearing on the personal interest of director

5. Material asset or derivatives transactions

6. Material monetary loans, endorsements or guarantees

7. Offering, issuance or private placement of any equity-type securities

8. Hiring or dismissal of an attesting CPA, or the compensation given thereto and performance, qualification and independence of CPAs

9. Appointment or discharge of financial, accounting or internal auditing officers

10. Financial reports

11. Review and discuss the matters related to the annual profit distributions

12. Review and discuss other material matters required by the Company or the competent authorities

 

The term of office of the current Audit Committee is from May 18, 2023 to May 17, 2026

Title Name Educational Background and Career Experience
Convener Pao-Shi Sheng Bachelor of Economics, University of California, Berkeley
Chairman and General Manager of Bora Pharmaceutical Co., Ltd.
Chairman, Union Chemical & Pharmaceutical Co., Ltd.
Director, Wellpool Co., Ltd.
Chairman, Bao Lei Co., Ltd.
Chairman, Rui Bao Xin Investment Co., Ltd.
Independent director, Gamania Digital Entertainment Co., Ltd.
Independent director, BIONET Corp.
Chairman, Bora Health Co., Ltd.
Chairman, Bora Pharmaceutical Laboratories Inc.
Chairman, Bao En International Co., Ltd.
Chairman, Jia Xi International Co., Ltd.
Chairman, Bora Management Consulting Co., Ltd.
Chairman, Bora Biologics Co., Ltd.
Chairman, Synpac-kingdom pharmaceutical Co., Ltd.
Member Nai-Jen Yeh Electrical and Computer Engineering, Tamkang University
R&D Vice President, Episil Technologies Inc.
R&D Vice President, Miracle Technology Co., Ltd.
General Manager of Asia region, Princeton Technology Co., Ltd.
Manufacturing Manager, United Microelectronics Corp.
Member Chien-Wei Chen EMBA of Taiwan- Fudan University
EMBA of National Taiwan University of Science and Technology
Industrial Engineering and Management, National Taiwan University of Science and Technology
President, Technology Unlimited Corp and its Subsidiaries
Chairman, Technology Created Medicine Corporation
Chairman, Sparkle Computer Co., Ltd.
Representative of juridical person director of Rigo Global Co., Ltd.
Independent Director, Aewin Technologies Co., Ltd.
Director, Curation Mobility Corporation

 

Operation of the Audit Committee

Attendance Record of the Audit Committee in 2023

Name Number of Meetings Attendance Absence or Attendance by Proxy Rate Remarks
Yong-Sheng Liu 2 2 0 100

May 18, 2023
Dsmissal

Ciou-Lin Chen 2 2 0 100
Pei-Jun Wu 2 2 0 100
Pao-Shi Sheng 2 2 0 100

May 18, 2023
New appointment

Nai-Jen Yeh 2 2 0 100
Chien-Wei Chen 2 2 0 100

 

 

Resolutions of the Audit Committee in 2023

Dates of Audit Committee meetings Contents of motion
1st Session of the 3rd Audit Committee in 2023
Feb. 21, 2023
Internal audit report.
The company’s decision of altering its accountant visa.
The evaluation of the suitability and independence of appointed CPAs.
2022 Financial statements.
2022 Earnings distribution.
Revised " Operational Procedures for Loaning Funds to Others”
2022 Statement of Internal Control System.
2nd Session of the 3rd Audit Committee in 2023
May 2, 2023
Internal audit report.
Q1 2023 Financial statements.
1st Session of the 4th Audit Committee in 2023
Aug. 1, 2023
Internal audit report.
Internal auditors’ evaluation report
Q2 2023 Financial statements.
Discussion on the amendment of the Company's "General Principles of Pre-Approved Non-Assurance Service
Policy"
2nd Session of the 4th Audit Committee in 2023
Oct. 26, 2023
Internal audit report.
Q3 2023 Financial statements.
2023 The delegation compensation of CPAs.
2024 Internal audit plan.

Independent directors’ objections, reservations, or major suggestions: None.

Resolution of the Audit Committee and the Company’s response to the Audit Committee’s Opinion: The members of the Audit Committee unanimously approved all the resolutions, and the Board of Directors approved all such resolutions recommended by the Audit Committee.

The Company’s Compensation Committee was set up in December 2011, which is composed of all independent directors. The Compensation Committee must exercise the duty of care as a good administrator to faithfully perform the following functions.

 Compensation Committee Scope of duties

1. Establish a policy, system, standard and structure for directors’ and managers’ compensation and review them periodically.

2. Decide compensation of directors and managers and carry out periodic evaluations.

 The term of office of the current Compensation Committee is from May 18, 2023 to May 17, 2026.

Title Name Educational Background and Career Experience
Convener Nai-Jen Yeh Electrical and Computer Engineering, Tamkang University
R&D Vice President, Episil Technologies Inc.
R&D Vice President, Miracle Technology Co., Ltd.
General Manager of Asia region, Princeton Technology Co., Ltd.
Manufacturing Manager, United Microelectronics Corp.
Member Pao-Shi Sheng Bachelor of Economics, University of California, Berkeley
Chairman and General Manager of Bora Pharmaceutical Co., Ltd.
Chairman, Union Chemical & Pharmaceutical Co., Ltd.
Director, Wellpool Co., Ltd.
Chairman, Bao Lei Co., Ltd.
Chairman, Rui Bao Xin Investment Co., Ltd.
Independent director, Gamania Digital Entertainment Co., Ltd.
Independent director, BIONET Corp.
Chairman, Bora Health Co., Ltd.
Chairman, Bora Pharmaceutical Laboratories Inc.
Chairman, Bao En International Co., Ltd.
Chairman, Jia Xi International Co., Ltd.
Chairman, Bora Management Consulting Co., Ltd.
Chairman, Bora Biologics Co., Ltd.
Chairman, Synpac-kingdom pharmaceutical Co., Ltd.
Member Chien-Wei Chen EMBA of Taiwan- Fudan University
EMBA of National Taiwan University of Science and Technology
Industrial Engineering and Management, National Taiwan University of Science and Technology
President, Technology Unlimited Corp and its Subsidiaries
Chairman, Technology Created Medicine Corporation
Chairman, Sparkle Computer Co., Ltd.
Representative of juridical person director of Rigo Global Co., Ltd.
Independent Director, Aewin Technologies Co., Ltd.
Director, Curation Mobility Corporation

 

 Operation of the Compensation Committee

Attendance Record of the Compensation Committee in 2023

Name Number of Meetings Attendance Absence or Attendance by Proxy Rate Remarks
Ciou-Lin Chen 1 1 0 100


May 18, 2023
Dismissal

Yong-Sheng Liu 1 1 0 100
Pei-Jun Wu 1 1 0 100
Nai-Jen Yeh 1 1 0 100


May 18, 2023
New appointment

Pao-Shi Sheng 1 1 0 100
Chien-Wei Chen 1 1 0 100

 

Resolutions of the Compensation Committee in 2023

Dates of Compensation Committee meetings Contents of motion
1st Session of the 5th Compensation Committee in 2023
Feb. 21, 2023

Distribution of the Company's fiscal year 2022 compensation to employee and directors.
In 2022, our company anticipates implementing a salary adjustment plan.
The company's executive compensation plan for the year 2022.

1st Session of the 6th Compensation Committee in 2023
Aug. 1, 2023
The remuneration proposal for the newly appointed Chairman of our company.

Resolution of the Compensation Committee and the Company’s response to the Compensation Committee’s Opinion::
The members of the Compensation Committee unanimously approved all the resolutions, and the Board of Directors approved all such resolutions recommended by the Compensation Committee.

 

The Company’s Nominate Committee was set up in November 2022, which is composed of all independent directors, the Committee possesses expertise in “Management /Corporate Governance”, Meet the professional competencies required by the committee. With authorization from the board of directors, the Committee shall exercise the due care of a good administrator to faithfully perform the following duties and shall submit its proposals to the board for discussion.

 Nominate Committee Scope of duties

1. Laying down the standards of independence and a diversified background covering the expertise, skills, experience, gender, etc. of members of the board, and senior executives, and finding, reviewing, and nominating candidates for directors, and senior executives based on such standards.

2. Establishing and developing the organizational structure of the board and each committee, and evaluating the performance of the board, each committee, and each director and senior executive and the independence of the independent directors.

3. Establishing and reviewing on a regular basis programs for director continuing education and the succession plans of directors and senior executives.

4. Establishing corporate governance guidelines of the Company.


The term of office of the current Nominate Committee is from May 18, 2023 to May 17, 2026

Title Name Educational Background and Career Experience Professional Qualification
Convener Chien-Wei Chen EMBA of Taiwan- Fudan University
EMBA of National Taiwan University of Science and Technology
Industrial Engineering and Management, National Taiwan University of Science and Technology
President, Technology Unlimited Corp and its Subsidiaries
Chairman, Technology Created Medicine Corporation
Chairman, Sparkle Computer Co., Ltd.
Representative of juridical person director of Rigo Global Co., Ltd.
Independent Director, Aewin Technologies Co., Ltd.
Director, Curation Mobility Corporation
Management
Corporate
Governance
Member Pao-Shi Sheng Bachelor of Economics, University of California, Berkeley
Chairman and General Manager of Bora Pharmaceutical Co., Ltd.
Chairman, Union Chemical & Pharmaceutical Co., Ltd.
Director, Wellpool Co., Ltd.
Chairman, Bao Lei Co., Ltd.
Chairman, Rui Bao Xin Investment Co., Ltd.
Independent director, Gamania Digital Entertainment Co., Ltd.
Independent director, BIONET Corp.
Chairman, Bora Health Co., Ltd.
Chairman, Bora Pharmaceutical Laboratories Inc.
Chairman, Bao En International Co., Ltd.
Chairman, Jia Xi International Co., Ltd.
Chairman, Bora Management Consulting Co., Ltd.
Chairman, Bora Biologics Co., Ltd.
Chairman, Synpac-kingdom pharmaceutical Co., Ltd.
Management
Corporate
Governance
Member Nai-Jen Yeh Electrical and Computer Engineering, Tamkang University
R&D Vice President, Episil Technologies Inc.
R&D Vice President, Miracle Technology Co., Ltd.
General Manager of Asia region, Princeton Technology Co., Ltd.
Manufacturing Manager, United Microelectronics Corp.
Management
Corporate
Governance

 

 Operation of the Nominate Committee

Attendance Record of the Nominate Committee in 2023

Name Number of Meetings Attendance Absence or Attendance by Proxy Rate Remarks
Pei-Jun Wu 1 1 0 100

May 18, 2023
Dismissal

Yong-Sheng Liu 1 1 0 100
Fu-Chi Teng 1 1 0 100
Chien-Wei Chen 1 1 1 100

May 18, 2023
New appointment

Pao-Shi Sheng 1 0 1 0
Nai-Jen Yeh 1 1 1 100

 

Resolutions of the Nominate Committee in 2023

Dates of Compensation Committee meetings Contents of motion
1st Session of the 1th Nominate Committee
in 2023 April. 06, 2023
The company's board of directors nomination and review of the list of director candidates.
1st Session of the 2nd Nominate Committee in 2023
December. 19, 2023
To approve revisions to Code of Corporate Governance.

Resolution of the Nominate Committee and the Company’s response to the Nominate Committee’s Opinion::
The members of the Nominate Committee unanimously approved all the resolutions, and the Board of Directors approved all such resolutions recommended by the Nominate Committee.

1. Independent directors and internal auditors communication:

(1) Provide audit progress reports to independent directors at least once a year, and reports to independent directors according to the Company’s annual audit plans and internal control follow-up procedures.
(2) At the end of each month, the head of Internal Audit send the audit and follow-up reports for the preceding month, and reports to independent directors according to the Company’s annual audit plans and internal control follow-up procedures. Provide audit progress reports to independent directors at least once a quarter. If material unusual matters occur during the auditing process, the head of Internal Audit will produce a report and submit to the independent directors immediately.
(3) If there were abnormal events, independent directors and the internal auditors could communicate when necessary.

The independent directors communicated well with internal audit managers.

2. The major matters of the communications between independent directors and internal auditors:
Meeting date Attendees Communication Highlights Summary Communicate results
2023/05/02 Independent Director
Yong-Sheng Liu
Recommendations from substantive examination of TWSE and improvement reports of the Company.
Special audit report.
Head of internal auditor responds to questions raised in the meeting.
Met with no objections from the independent directors after extensive communication between independent directors and the head of internal auditor.
Independent Director
Ciou-Lin Chen
Head of internal auditor
Hsin-Chien Lee
 
3. Independent directors and independent auditors (CPA):

(1) Apart from the once-annually face-to-face corporate governance meetings held by the audit committee and CPA, CPA may use written forms of communication when necessary. The scope of which includes independent auditors’ report on the independence of the Company’s consolidated financial reports and related responsibilities; audit plans and related matters; major matters relating to the audit (such as adjustment of journal entries and material weaknesses in internal control); findings of the audit report and review of the consolidated financial reports.
(2) If there were abnormal events, independent directors and CPA could communicate when necessary.

The independent directors communicated well with CPA.

4. The major matters of the communications between independent directors and CPA:
Meeting date Attendees Communication Highlights Summary Communicate results
2023/12/19 Independent Director
Nai-Jen Yeh
Review and communication with the CPA regarding audit planning in the 2023 consolidated financial report.
Changes in significant accounting estimates in 2023.
Review and communication the feasibility and impact of regulation amendments on the report.
CPA responds to questions raised in the meeting.
Met with no objections from the independent directors after extensive communication between independent directors and the CPA.
Independent Director
Chien-Wei Chen
Chien-Liang Liu CPA,
Deloitte & Touche
Wen-Chin Lin CPA,
Deloitte & Touche
Hsiu-Hui Fan Senior Manager,
Deloitte & Touche
Head of internal auditor
Hsin-Chien Lee